Your selection basket is empty.
Define a selection of ETFs which you would like to compare.
Add an ETF by clicking "Compare" on an ETF profile or by checkmarking an ETF in the ETF search.
| Index | Harbor Health Care |
| Investment focus | Equity, World, Health Care |
| Fund size | EUR 14 m |
| Total expense ratio | 0.89% p.a. |
| Replication | Physical (Full replication) |
| Legal structure | ETF |
| Strategy risk | Actively managed |
| Sustainability | No |
| Fund currency | USD |
| Currency risk | Currency unhedged |
| Volatility 1 year (in EUR) | 22.81% |
| Inception/ Listing Date | 4 April 2019 |
| Distribution policy | Accumulating |
| Distribution frequency | - |
| Fund domicile | Ireland |
| Fund Provider | HANetf |
| Fund Structure | Open-ended Investment Company (OEIC) |
| UCITS compliance | Yes |
| Administrator | J.P. Morgan Administration Services (Ireland) Limited |
| Investment Advisor | |
| Custodian Bank | J.P. Morgan SE - Dublin Branch |
| Revision Company | Ernst and Young |
| Fiscal Year End | 31 March |
| Swiss representative | Waystone |
| Swiss paying agent | Helvitsche Bank |
| Germany | 30% tax rebate |
| Switzerland | ESTV Reporting |
| Austria | Tax Reporting Fund |
| UK | UK Reporting |
| Indextype | Total return index |
| Swap counterparty | - |
| Collateral manager | |
| Securities lending | No |
| Securities lending counterparty |
| Eli Lilly & Co. | 9.22% |
| Ascendis Pharma A/S | 8.94% |
| Legend Biotech | 7.40% |
| UnitedHealth Group | 5.92% |
| Masimo | 5.86% |
| AbbVie, Inc. | 4.41% |
| DexCom | 4.34% |
| Vaxcyte | 4.05% |
| ICON plc | 3.96% |
| Rhythm Pharmaceuticals | 3.67% |
| United States | 78.52% |
| Ireland | 3.98% |
| Netherlands | 1.23% |
| Other | 16.27% |
| Health Care | 83.74% |
| Other | 16.26% |
| YTD | +10.00% |
| 1 month | +3.68% |
| 3 months | +11.04% |
| 6 months | +19.52% |
| 1 year | +3.07% |
| 3 years | -2.63% |
| 5 years | -19.45% |
| Since inception (MAX) | +1.59% |
| 2024 | -3.47% |
| 2023 | -1.92% |
| 2022 | -25.63% |
| 2021 | +1.00% |
| Volatility 1 year | 22.81% |
| Volatility 3 years | 20.16% |
| Volatility 5 years | 22.60% |
| Return per risk 1 year | 0.15 |
| Return per risk 3 years | -0.04 |
| Return per risk 5 years | -0.18 |
| Maximum drawdown 1 year | -22.24% |
| Maximum drawdown 3 years | -26.56% |
| Maximum drawdown 5 years | -46.71% |
| Maximum drawdown since inception | -46.71% |
| Listing | Trade Currency | Ticker | Bloomberg / iNAV Bloomberg Code | Reuters RIC / iNAV Reuters | Market Maker |
|---|---|---|---|---|---|
| gettex | EUR | W311 | - - | - - | - |
| Borsa Italiana | EUR | WELL | WELL IM WELLEUIV | WELL.MI WELLEURINAV=SOLA | RBC Europe Ltd |
| Euronext Paris | EUR | WELL | WELL FP WELLEUIV | WELP.PA WELLEURINAV=SOLA | RBC Europe Ltd |
| London Stock Exchange | GBX | WELP | WELP LN | WELP.L | RBC Europe Ltd |
| London Stock Exchange | USD | WELL | WELL LN | HAWELL.L | RBC Europe Ltd |
| London Stock Exchange | GBP | - | RBC Europe Ltd | ||
| SIX Swiss Exchange | CHF | WELL | WELL SW WELLEUIV | WELL.S WELLEURINAV=SOLA | RBC Europe Ltd |
| XETRA | EUR | W311 | W311 GY WELLEUIV | W311.DE WELLEURINAV=SOLA | RBC Europe Ltd |
| Fund name | Fund Size in m € (AuM) | TER p.a. | Distribution | Replication |
|---|---|---|---|---|
| L&G Healthcare Technology & Innovation UCITS ETF USD Acc | 152 | 0.49% p.a. | Accumulating | Full replication |
| L&G Pharma Breakthrough UCITS ETF | 16 | 0.49% p.a. | Accumulating | Full replication |